NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 [1][2] - The presentation will include a corporate update and plans to launch a low-dose D-Cycloserine product, which has shown to more than double the effectiveness of Transcranial Magnetic Stimulation in treating depression [2] - NRx Pharmaceuticals is actively involved in treating veterans with suicidal depression and PTSD, collaborating with the US Department of Veterans Affairs [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [4] - The company is developing NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for treating suicidal bipolar depression [4] - NRx has recently re-filed an Abbreviated New Drug Application for NRX-100 and initiated a New Drug Application filing for the treatment of suicidal ideation in patients with depression [4] HOPE Therapeutics Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics [5] - The clinics will offer treatments such as ketamine, Transcranial Magnetic Stimulation, and Hyperbaric Oxygen Therapy for patients with suicidal depression and related disorders [5] - HOPE Therapeutics aims to enhance the clinical benefits of NMDA-targeted drug therapy through a digital therapeutic-enabled platform [5]